January 25th 2012 – In an October issue of Ophthalmology, it was reported that astronauts who spend six months or longer in space may begin to experience visual changes, changes that may last even after returning to Earth. In a study conducted, seven astronauts spent at least six consecutive months in space were observed, and […]

January 13th 2012- Contact lenses, a Class II medical device, are already used by millions of Americans to see. However, exciting news from the University of Washington shows that maybe, in the relatively near future, they may be able to monitor health. “Smart Lenses,” a new generation of lenses, are specially designed with wireless technology, circuitry,

January 7th 2012 – The FDA has given approval to ABB Concise to produce silicon hydrogel specialty contact lenses made from 74% H2O Definitive material with a Dk of 60. The specialty lenses will include designs for multifocal, toric, and irregular corneas. These new products will be available in the first quarter of 2012. Article By:

January 7th 2012- Glaucoma, right behind cataracts is the second leading cause of blindness in the world. January marks National Glaucoma Awareness Month. Some of the biggest groups and organizations in eyecare are educating the public about this blinding disease and to get comprehensive eye exams such as the American Optometric Association, Prevent Blindness America, the

Ophthalmic Resources On Demand Tool Takes Home Two eHealthcare Leadership Awards January 7th 2011- The Ophthalmic Resources On Demand tool launched by the American Optometric Association took home two eHealthcare Leadership Awards at the 15th Annual Healthcare Internet Conference in November. Selected from 1,200 entries, the AOA platform won Platinum Award for Best Health/Healthcare Content

Jauary 7th 2012- Wet AMD poses a risk of blindness in seniors. Recent research has suggested that taking a daily aspirin may double the risk of developing wet AMD. The Journal Ophthalmology reported that daily aspirin use was associated with the onset of late-stage wet AMD and the onset of early dry AMD. The results of

December 22nd 2011 – It was originally determined that there is little risk that Lucentis, an AMD drug, raises IOP. However, there has recently been some conflicting evidence spurred by a Mayo Clinic ophthalmologist who noticed an increase in IOP in some of her patients receiving Lucentis. To assist in this discrepancy, a retrospective study

Update about ‘Allow Optometrists in Puerto Rico to prescribe therapeutic pharmaceutical agents!’ on Change.org Colleagues and friends: The petition reached today the landmark 800 signatures! We still need 200 more signatures to reach the 1,000 goal. The government has started to acknowledge the petition and I have the confident that the issue would be resolved